Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.5b

Intellia Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Intellia Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-19.9%

Buyback Yield

Total Shareholder Yield-19.9%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Nov 19

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

Nov 11

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Nov 05

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Oct 25

Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case

Sep 25

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Sep 07
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)

Aug 03

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Jun 06
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Jun 05

Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

May 14
Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

May 13

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01
Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Aug 06
Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Aug 04

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Jul 28

Intellia Therapeutics: Several Catalysts Expected For H2 2022

May 12

Intellia: One Patent Ruling Turns The Industry Upside Down

Mar 09

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Feb 25

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09
Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31
We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.


Dividend Yield vs Market

Intellia Therapeutics Dividend Yield vs Market
How does NTLA dividend yield compare to the market?
SegmentDividend Yield
Company (NTLA)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (NTLA) (up to 3 years)0%

Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NTLA's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTLA has not reported any payouts.


Discover strong dividend paying companies